CUTANEOUS ADVERSE EVENTS IN CHILDREN TREATED WITH BRAF-INHIBITOR VEMURAFENIB FOR REFRACTORY BRAF (V600E) MUTATED LANGERHANS CELL HISTIOCYTOSIS: A EUROPEAN COHORT STUDY - Archive ouverte HAL Access content directly
Conference Papers Year : 2019

CUTANEOUS ADVERSE EVENTS IN CHILDREN TREATED WITH BRAF-INHIBITOR VEMURAFENIB FOR REFRACTORY BRAF (V600E) MUTATED LANGERHANS CELL HISTIOCYTOSIS: A EUROPEAN COHORT STUDY

(1) , , (2) , (3) , (4) , (5) , (6) , , , (7) , (8)
1
2
3
4
5
6
7
8

Domains

Life Sciences [q-bio]

Valerie TALY  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-02413491

Submitted on : Monday, December 16, 2019-11:21:27 AM

Last modification on : Thursday, August 4, 2022-5:28:04 PM

Not file

Dates and versions

inserm-02413491 , version 1 (16-12-2019)

Identifiers

  • HAL Id : inserm-02413491 , version 1

Cite

Mathilde Tardieu, Sophie Duvert Lehembre, Islam Amine Larabi, Johannes Visser, Caroline Hutter, et al.. CUTANEOUS ADVERSE EVENTS IN CHILDREN TREATED WITH BRAF-INHIBITOR VEMURAFENIB FOR REFRACTORY BRAF (V600E) MUTATED LANGERHANS CELL HISTIOCYTOSIS: A EUROPEAN COHORT STUDY. 34th Annual Meeting of the Histiocyte Society Lisbon, Portugal, October 22–23, 2018, Oct 2019, Lisbon, Portugal. pp.S46-S47. ⟨inserm-02413491⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM USPC SORBONNE-UNIVERSITE SU-MEDECINE UNIV-PARIS
50 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More